Detailed narrative
FY25 Performance Overview and Challenges
Aimco Pesticides experienced a challenging FY25, with the top-line remaining largely flat and marginal sales degrowth compared to the previous financial year. Profitability margins were under significant pressure, leading to observed EBITDA losses and a negative PAT level for the year. This performance was primarily attributed to heightened competitive pressures and pricing reductions within the broader agrochemical industry.
Active Ingredient Division: Volume Growth vs. Price Erosion
The active ingredient division faced intense price competition, particularly from Chinese manufacturers, which led to lower product realizations across global markets. Despite achieving a 25% volume growth in active ingredients, this was entirely offset by value erosion, resulting in no significant change to the segment's top-line. Gross margins in key active ingredient products compressed significantly, falling from a range of 20-30% to 12-20%.
Brand Business Resilience and Growth Strategy
In contrast to the active ingredient segment, the domestic brand business demonstrated resilience, growing 15% in FY25. For FY26, the company is targeting an aggressive 20% growth in this segment. This growth will be driven by expanding the product portfolio with 5 new molecules this year (following 6 additions last year) and increasing market penetration in Central and North India, areas where the company previously had limited presence. Gross margins in the brand business remain healthier, ranging from 30-35%.
International Expansion and Brazil Market Penetration
The company has secured Bifenthrin registration in Brazil, with Triclopyr registration expected soon. Initial sales of Triclopyr from Brazil are projected to be 200-300 tons, equating to approximately ₹100 crores. However, management noted acute price competition from Chinese companies in Brazil, indicating that market penetration will require strategic efforts. Aimco is also pursuing registrations in other international markets like Australia, Indonesia, Malaysia, and the US to diversify its export business.
New Product Development and Commercialization
Aimco Pesticides has commenced manufacturing three new molecules, with two showing stabilized production and comfortable gross margins. One of these, Ethiprole, an insecticide, holds significant B2B potential, and the company is actively pursuing large B2B opportunities. While these new molecules are in early stages for scale-up, increased production is planned for FY26, with results expected to be visible in the next financial year.
Capital Infusion and Focus on Profitability for FY26
To support its operations and growth initiatives, promoters infused additional capital through a preferential issue of 2 lakh shares. Following two challenging years, the company's primary goal for FY26 is to return to profitability and avoid negative EBITDA. This will be achieved through a continued focus on cost reduction, operational efficiencies, and leveraging the recent upward movement in prices observed since April 2025, which has improved margins.
Inventory Management and Price Trend Outlook
The company acknowledged a 40% year-on-year increase in inventories but confirmed that levels have been 'considerably brought down' from the last quarter, with ongoing efforts to further reduce them. Management noted that prices have shown an upward movement from April 2025, leading to improved margins compared to Q4 FY25. However, they remain cautious, stating that the full year's trajectory is yet to be seen, especially concerning potential raw material price volatility for products like Chlorpyrifos.